JPMorgan analyst Anupam Rama lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $34 from $39 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharma’s Earnings Call Highlights Growth and Challenges
- Day One price target lowered to $30 from $34 at JonesResearch
- Buy Rating on Day One Biopharmaceuticals: Strong Performance and Promising Future Prospects
- Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial
- Promising Growth and Strategic Advancements Drive Buy Rating for Day One Biopharmaceuticals